承慶堂品牌怎么样 申请店铺

我要投票 承慶堂在医疗器械行业中的票数:671 更新时间:2026-02-09
承慶堂是哪个国家的品牌?「承慶堂」是 安徽承庆堂国药股份有限公司 旗下著名品牌。该品牌发源于安徽省亳州市,由创始人李整风在2012-01-17期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力承慶堂品牌出海!将品牌入驻外推网,定制承慶堂品牌推广信息,可以显著提高承慶堂产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

承慶堂怎么样

安徽承庆堂国药股份有限公司(原亳州正丰医药有限责任公司)是于2001年投资建设的集医疗器械生产与销售一体化公司,是一家集医疗器械的技术研发、技术咨询为产业核心,采用国际OEM模式,以掌控知识产权为入手、以医药科研为主的企业,主打“承庆堂”骨病系列外用贴剂产品,以疗效显著、品质稳定深得广大骨科医院及消费者的认可和好评。公司在医药行业经过短短几年的发展历程,依靠自身产品的绝对疗效已形成了骨病系列外用贴剂的知名品牌。“品质决定品牌”,创造骨病系列外用贴剂的医药品牌是正丰医药人孜孜不倦和执着追求的目标。

公司拥有一支团结、创新、奋进的技术研发队伍,在公司全体员工的共同努力下,企业坚持走专业化道路,形成了“材料来源基地化,检测手段科学化,制作工艺规范化,贴剂质量标准化,设计包装规格化”的“五化”管理模式,产品“选料上乘,工艺考究,疗效显著”。提升了“承庆堂”品牌的知名度和美誉度。始终坚持靠诚信打造自身品牌、靠质量占领市场先机、靠服务赢得行业机遇、靠管理推动企业发展的理念,在严峻的医药行业形势下,注重发挥自身优势,做大做强主营业务,我们坚信“一生只做一件事”,在同行业内取得了骄人的业绩,公司在发展过程中,得到了各级领导和相关职能管理部门的正确指引和极大的关怀,在广大医药流通企业和商业客户的支持下,在全国药业行业中,凭借自身实力和产品品质,铸就了企业在医药行业及广大骨科医院的巩固地位。目前,公司已与国内多家骨科医院和众多客户建立了紧密、稳固的合作关系,形成了强大的销售网络和品牌优势。公司也一直专注于现代企业制度的建设,目前已经在企业的产权结构、运营模式、管理制度、业务流程上达到了一定水平,并形成了自己的特色。

公司自2007年就尝试运作终端销售模式,即在有条件的骨科医院设立精品药房,截至目前已在国内多家骨科医院建立了上百家精品药房,此模式的成功运作,有利于实现名企、名院、名医、名品的优化组合,扩大医疗机构的服务范围,为患者提供疗效显著、价格合理的诚信医疗服务。我们诚邀各大骨科医院垂询来访,共筑合作平台,实现医药携手共赢发展。

在如今医药行业新的竞争和挑战中,我们将拥有更加广阔的医药市场。“海内存知己,天涯若比邻”,公司愿与全国各大骨科医院、连锁药房及各界的朋友真诚合作、共创辉煌!



Anhui chengqingtang State Pharmaceutical Co., Ltd. (formerly Bozhou Zhengfeng Pharmaceutical Co., Ltd.) is an integrated production and sales company of medical devices invested and constructed in 2001. It is an enterprise that focuses on technical research and development and technical consultation of medical devices, adopts the international OEM mode, controls intellectual property rights and focuses on medical research, and focuses on "chengqingtang" osteopathy A series of external patch products, with remarkable curative effect and stable quality, have won the recognition and praise of orthopedic hospitals and consumers. After just a few years of development in the pharmaceutical industry, relying on the absolute efficacy of its own products, the company has formed a well-known brand of bone disease series external patches. "Quality determines the brand" and creating a brand of external use of orthopedic patches is the goal of Zhengfeng pharmaceutical people. The company has a united, innovative and progressive technology research and development team. With the joint efforts of all employees, the company adheres to the path of specialization, forming a "five chemical" management mode of "base of material sources, scientific detection means, standardized production process, standardized paste quality, standardized design and packaging". The product "selects the best materials, exquisite technology, and curative effect" Remarkable. It has improved the popularity and reputation of chengqingtang brand. We always adhere to the concept of building our own brand by integrity, seizing the market opportunity by quality, winning industry opportunities by service, and promoting enterprise development by management. Under the severe situation of the pharmaceutical industry, we pay attention to giving full play to our own advantages and making our main business bigger and stronger. We firmly believe that "only one thing in life" has made remarkable achievements in the same industry. In the process of development, the company has obtained With the correct guidance and great care of leaders at all levels and relevant functional management departments, supported by the majority of pharmaceutical circulation enterprises and commercial customers, and with its own strength and product quality in the national pharmaceutical industry, the company has established a firm position in the pharmaceutical industry and the majority of orthopedic hospitals. At present, the company has established close and stable cooperative relations with many orthopedic hospitals and customers in China, forming a strong sales network and brand advantages. The company has also been focusing on the construction of modern enterprise system. At present, it has reached a certain level in the property right structure, operation mode, management system and business process of the enterprise, and has formed its own characteristics. Since 2007, the company has tried to operate terminal sales mode, that is, to set up boutique pharmacies in conditional orthopedic hospitals. Up to now, hundreds of boutique pharmacies have been set up in many orthopedic hospitals in China. The successful operation of this mode is conducive to the realization of the optimized combination of famous enterprises, famous hospitals, famous doctors and famous products, the expansion of the service scope of medical institutions, and the provision of significant curative effect and reasonable price for patients The integrity of medical services. We sincerely invite all orthopedic hospitals to visit us and build a cooperation platform to achieve win-win development of medicine. In today's new competition and challenges in the pharmaceutical industry, we will have a broader pharmaceutical market. "Friends in the sea, the end of the world is like a neighbor", the company is willing to sincerely cooperate with all major orthopedic hospitals, chain pharmacies and friends from all walks of life to create brilliant!

本文链接: https://brand.waitui.com/8a4ae9536.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

国联民生:拟向民生证券增资2亿元

2月8日,国联民生公告,公司拟向民生证券增资2亿元,增资后公司对民生证券持股比例不变。本次增资的资金来源为公司向特定对象发行股票募集的配套资金,用于民生证券财富管理业务发展和信息技术投入。(第一财经)

2小时前

明冠新材:终止太阳能背板及功能性膜生产基地项目投资协议

2月8日,明冠新材公告,公司决定终止与肥东县人民政府签订的太阳能背板及功能性膜生产基地项目投资合作协议。该项目总投资预计50亿元,目前公司正积极配合肥东县政府办理定制物业的竣工验收等后续工作。自2023年第四季度起,光伏行业已出现产能过剩苗头,产业链产品价格竞争随之加剧,行业处于产业调整周期,2024年和2025年度出现光伏行业普遍亏损。公司管理层在对市场变化认真分析及谨慎研判的基础上,考虑行业内卷导致光伏封装材料盈利能力逐步下降,加之2025年行业竞争白热化且周期性调整尚未呈现明显好转,若继续推进明冠合肥项目,将不可避免地推高公司整体运营成本。(界面新闻)

2小时前

马斯克:是时候大规模重返月球了

2月8日,马斯克发帖表示,是时候大规模重返月球了。此外,有消息称SpaceX正在奥斯汀和西雅图招聘工程师,以开发人工智能卫星和太空数据中心。马斯克转发相关帖子并回复称:是真的。(财联社)

2小时前

杉杉股份:若重整成功,公司实际控制人将变更为安徽省国资委

2月8日,杉杉股份公告称,公司控股股东杉杉集团及其全资子公司宁波朋泽贸易有限公司、杉杉集团管理人与重整投资人安徽皖维集团有限责任公司和宁波金融资产管理股份有限公司签署了《重整投资协议》。若本次重整成功,公司的控制权将发生变更,公司控股股东将变更为皖维集团,公司实际控制人将变更为安徽省国资委。(财联社)

2小时前

国投白银LOF:提示交易价格溢价风险并公布停复牌安排

2月8日,国投白银LOF公告称,近期其二级市场交易价格明显高于基金份额净值,溢价幅度较大。为保护投资者利益,基金将于2026年2月9日开市起至10:30停牌,10:30复牌。若当日溢价幅度未有效回落,基金有权采取进一步措施。自2026年1月28日起,基金已暂停申购(含定期定额投资)业务,恢复时间另行公告。目前基金运作正常,无应披露未披露重大信息。(每日经济新闻)

2小时前

本页详细列出关于承慶堂的品牌信息,含品牌所属公司介绍,承慶堂所处行业的品牌地位及优势。
咨询